Testing a Special Scan to Look at Cancer That Has Spread to the Brain
Original title: Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early first test of this scan in a small number of people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing whether a special type of scan can give doctors a clearer picture of cancer that has spread to the brain.
Who this trial is for. This trial is for people with cancer that has spread to the brain from another part of the body. It tests a scan called a PET/CT that uses a tracer called fluciclovine, given before and after treatment.
Where it stands. The team is watching how the tracer builds up in the brain spots over 60 minutes. They will compare the scans to MRI and to tissue test results. They also want to see if the scan can tell regrowing cancer apart from damage caused by radiation. The trial has not reported results yet.
What this means, and what it doesn't
What it could mean: If it works, this scan might one day help doctors understand brain spots that are hard to read on an MRI. Someone with cancer that has spread to the brain could ask their care team if this trial fits them. The trial team decides who can join.
What it doesn't mean: This trial is a test, not a proven tool. It is a scan, not a treatment for the cancer. Joining does not promise any benefit. It is not a cure.
Source: ClinicalTrials.gov, September 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.